Breaking News Instant updates and real-time market news.

ICPT

Intercept

$98.12

-15.36 (-13.54%)

08:40
09/13/17
09/13
08:40
09/13/17
08:40

Intercept letter doesn't change fundamental view of Ocaliva, says JMP Securities

JMP Securities analyst Liisa Bayko said the warning letter sent by Intercept to health care providers regarding post-marketing reports of liver issues and death in certain PBC patients highlights risks that were already known and doesn't change her fundamental view on Ocaliva. The analyst, who sees little read through to the ongoing Phase 3 REGENERATE trial in NASH patients and views yesterday's drop in Intercept shares as an overreaction, keeps an Outperform rating and $150 price target on the stock.

ICPT Intercept
$98.12

-15.36 (-13.54%)

09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.
09/13/17
SBSH
09/13/17
NO CHANGE
Target $150
SBSH
Buy
Intercept price target lowered to $150 from $240 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.
09/13/17
MSCO
09/13/17
NO CHANGE
MSCO
Underweight
Intercept talks raise concern of potentially larger issue, says Morgan Stanley
Morgan Stanley analyst Andrew Berens noted that Intercept attended the firm's healthcare conference and discussed its recently sent "Dear Healthcare Provider" letter regarding liver toxicity seen with Ocaliva in some PBC patients. Discussion at the event suggests Ocaliva may have direct effect on liver toxicity in the presence of cholestasis and/or high drug levels, according to Berens, who sees this issue having significant implications for the drug, especially in NASH patients, he tells investors. Berens keeps an Underweight rating and $75 price target on Intercept shares, which closed yesterday down 13.5% at $98.12.
09/13/17
BMOC
09/13/17
NO CHANGE
BMOC
Intercept should be bought on weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says the letter sent by Intercept to healthcare providers regarding its Ocaliva drug relates to failure by doctors to adhere to dose adjustments recommended in its label. Since no new adverse events were cited in the letter, the analyst does not expect any changes to the label. He continues to expect strong Ocaliva prescriptions to result in the company reporting beat and raise Q3 results, and he recommends buying the stock on weakness. He keeps a $221 price target and an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

CSX

CSX

$58.13

-1.12 (-1.89%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Earnings
CSX reports Q4 EPS 64c, consensus 56c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 01

    Mar

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Earnings
Interactive Brokers reports Q4 EPS (2c), consensus 40c »

Excluding the impact of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

DG

Dollar General

$98.50

-0.6 (-0.61%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Initiation
Dollar General initiated  »

Dollar General initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMS

Maximus

$71.42

-0.47 (-0.65%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Hot Stocks
Maximus appoints Bruce Caswell as CEO after retirement of Richard Montoni »

Maximus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Syndicate
HTG Molecular files to sell $10M shares of common stock »

Leerink Partners LLC and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Obalon Therapeutics files to sell $35M on common stock »

UBS Investment Bank,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Breaking Syndicate news story on Nutanix »

Nutanix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

UAA

Under Armour; also tag UA

$13.63

-1.49 (-9.85%)

15:55
01/16/18
01/16
15:55
01/16/18
15:55
Options
Under Armour Class A put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:55
01/16/18
01/16
15:55
01/16/18
15:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

LVS

Las Vegas Sands

$72.58

1.56 (2.20%)

15:52
01/16/18
01/16
15:52
01/16/18
15:52
Periodicals
Breaking Periodicals news story on Las Vegas Sands »

Las Vegas Sands added as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$32.35

1 (3.19%)

15:48
01/16/18
01/16
15:48
01/16/18
15:48
Hot Stocks
HomeStreet raises company-wide minimum wage to $15 per hour »

HomeStreet announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HUM

Humana

$270.41

2.39 (0.89%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Options
Humana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

USB

U.S. Bancorp

$57.46

0.48 (0.84%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Hot Stocks
U.S. Bancorp names CEO Andy Cecere chairman of the board »

U.S. Bancorp, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LADR

Ladder Capital

$14.53

0.94 (6.92%)

15:39
01/16/18
01/16
15:39
01/16/18
15:39
Upgrade
Ladder Capital rating change  »

Ladder Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

ONCE

Spark Therapeutics

$52.66

-1.41 (-2.61%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Hot Stocks
Spark Therapeutics treatment of hemophilia A granted FDA orphan status »

Spark Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PX

Praxair

$161.26

-2.89 (-1.76%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Options
$6M option print in Praxair as shares deflate »

$6M option print in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CGI

Celadon Group

$6.20

-0.4 (-6.06%)

15:26
01/16/18
01/16
15:26
01/16/18
15:26
Periodicals
Celadon Group mentioned cautiously again by Prescience Point 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGSE

RGS Energy

15:24
01/16/18
01/16
15:24
01/16/18
15:24
Hot Stocks
Iroquois Capital reports 6.3% stake in Real Goods Solar »

This activist stake held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$36.09

1.06 (3.03%)

15:20
01/16/18
01/16
15:20
01/16/18
15:20
Options
Notable spread in MGM as shares rally »

Notable spread in MGM as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
01/16/18
01/16
15:17
01/16/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
01/16/18
01/16
15:16
01/16/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$56.93

-0.73 (-1.27%)

15:15
01/16/18
01/16
15:15
01/16/18
15:15
Options
Continental Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

OLED

Universal Display

$196.60

-1.2 (-0.61%)

15:05
01/16/18
01/16
15:05
01/16/18
15:05
Options
Universal Display call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

FRME

First Merchants

$44.20

0.31 (0.71%)

15:05
01/16/18
01/16
15:05
01/16/18
15:05
Hot Stocks
First Merchants announces company-wide raise, bonuses »

First Merchants announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CEO

CNOOC

$159.15

-2.1 (-1.30%)

15:04
01/16/18
01/16
15:04
01/16/18
15:04
Downgrade
CNOOC rating change  »

CNOOC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.